- Founded
- 2011
- Employees
- 30
- Total Funding
- $272.5M
Founded by Mark W. Surber in 2011.
About Avalyn Pharma
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has demonstrated encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to...
Leadership at Avalyn Pharma
The team at the top of the org chart.
Lyn Baranowski
CEO
33 reports
Mark Surber
Founder & Chief Scientific Officer
1 report
Marc Schneebaum
CFO
2 reports
Howard M. Lazarus
Chief Medical Officer
9 reports
Melissa Rhodes
COO
3 reports
Douglas Carlson
Chief Financial Officer / Chief Business Officer
7 reports
Craig Conoscenti
Sr Vice President
4 reports
Susan Brancaccio
Senior Executive Assistant
Board
Niall O’Donnell
Chairman
Ketan Patel
Director
Sofia Ioannidou
Director
Tiba Aynechi
Director
Peter Moldt
Director
Open Jobs at Avalyn Pharma (6)
Similar companies hiring
Top employers in Medical